Mark Fladrich

Vorsitzender bei MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

67 Jahre

Health Technology

Consumer Services

Distribution Services

Profil

Mark Fladrich is currently Chairman at Qbiotics Pty Ltd., Chairman at Grünenthal Pharma SA since 2018, Chairman at Medical Developments International Ltd. starting in 2025, and Director at Grünenthal Ltd. since 2018.
Formerly, Mr. Fladrich was Chief Commercial Officer at Grünenthal GmbH.
Education includes an MBA from Macquarie University and an undergraduate degree from the University of South Australia.

Aktive Positionen von Mark Fladrich

Unternehmen	Position	Beginn
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED	Vorsitzender	01.12.2025
Grünenthal Pharma SA Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines	Vorsitzender	23.03.2018
Grünenthal Ltd. Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products	Direktor/Vorstandsmitglied	18.01.2018
Qbiotics Pty Ltd. Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers.	Vorsitzender	-

Alle aktiven Positionen von Mark Fladrich

Ehemalige bekannte Positionen von Mark Fladrich

Unternehmen	Position	Ende
Grünenthal GmbH Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Mark Fladrich im Detail an

Ausbildung von Mark Fladrich

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Mark Fladrich im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	7
Medical Developments International Ltd. Medical Developments International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical drugs & medical equipment	Health Technology
Grünenthal GmbH Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Manufactures medicines for pain management and related diseases	Health Technology
Macquarie University Macquarie University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of South Australia University of South Australia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Grünenthal Ltd. Grünenthal Ltd. Medical DistributorsDistribution Services Wholesales pharmaceutical products	Distribution Services
Grünenthal Pharma SA Grünenthal Pharma SA Pharmaceuticals: OtherHealth Technology Manufactures medicines	Health Technology
Qbiotics Pty Ltd. Qbiotics Pty Ltd. Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers.